ASCO GI Updates Provide Window Into Evolving HCC Treatment Paradigm
Experts discuss updated findings from key clinical trials in hepatocellular carcinoma presented during the 2024 Gastrointestinal Cancers Symposium.
Experts discuss updated findings from key clinical trials in hepatocellular carcinoma presented during the 2024 Gastrointestinal Cancers Symposium.
HHV-6B reactivation affects approximately half of all allogeneic hematopoietic cell transplant (HCT) recipients. HHV-6B is the most frequent infectious cause of encephalitis following HCT and…
Dr. Bose discusses the key findings from the COMFORT I and II trials and how the overall survival data has impacted the way he manages…
2023 Featured Articles July 13 – Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial Citation: van Hemert,…
An abstract is unavailable.
Health Canada has approved pembrolizumab plus chemotherapy for first-line, locally advanced, unresectable, or metastatic, HER2-negative gastric/GEJ cancer.
Registration for the OncoAlert ASCO 5k to be held on June 1st, 2024 at 7am local time and will start at the Hyatt Regency McCormick…
The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.
MRI-guided treatment could be used to optimize the duration of neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive breast cancer.
A unique approach combining genomic and sensitivity testing with machine learning was feasible for guiding treatment selection in pediatric cancers.
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Montgomery Cancer Center, Prattville Campus,…